On the 14th, Locomotive announced that Lim Jong-yoon, chairman of the Cori Group, has been appointed as the vice chairman (chairman of the board and representative) of Beijing Hanmi Pharmaceutical Co., Ltd., a subsidiary of Hanmi Pharmaceutical.
Chairman Lim is the eldest son of the founder's family of Hanmi Pharmaceutical.
According to Locomotive, Beijing Hanmi recently held a board meeting consisting of two directors from China Huayun Group and three directors from Hanmi Pharmaceutical and appointed Chairman Lim as vice chairman.
Beijing Hanmi is a company established in 1996 by Hanmi Pharmaceutical and a Chinese state-owned enterprise, Huayun Group.
In October last year, when the management rights dispute between the founder's family and their daughters intensified, Park Jae-hyun, CEO of Hanmi Pharmaceutical, who had been supported by the daughters, was appointed as the vice chairman of Beijing Hanmi Pharmaceutical. However, following the resolution of the management rights dispute in favor of the daughters on the 13th, the head has been replaced again. Previously, Lim Jong-yoon had served as vice chairman of Beijing Hanmi since 2005.
Locomotive announced that Beijing Hanmi completed the registration of three new directors: Kwon Yong-nam, head of the management support division; Seo Young, head of the research and development center; and Lee Sun-ro, representative of Cori Italy.
Kwon Yong-nam has been responsible for internal management, including finance and purchasing at Beijing Hanmi, starting from Hanmi Healthcare in 2006. Seo Young has led the research and development at the Beijing Cori Science and Technology Research and Development Center after working as a researcher at the Chinese Academy of Medical Sciences since 1989. Representative Lee Sun-ro joined the sales department of Hanmi Pharmaceutical in 1999 and has served as head of the planning department and management planning division at Beijing Hanmi.
However, Hanmi Pharmaceutical drew a line regarding the appointment of Chairman Lim Jong-yoon as vice chairman of Beijing Hanmi. An official from Hanmi Pharmaceutical noted, "Hanmi Pharmaceutical holds 73.7% equity in Beijing Hanmi Pharmaceutical," and added, "We will organize and release an official position later."
Meanwhile, the revenue of Beijing Hanmi Pharmaceutical, which was around 10 billion won in 2004, recorded 385.6 billion won last year. Beijing Hanmi has completed clinical development and approval for 20 pharmaceuticals based on its localization infrastructure in the global second-largest pharmaceutical market in China, worth 225 trillion won.